37,148 new COVID-19 cases in last 24 hours take India's tally to 11.55 lakh, death toll tops 28,000 | Check state-wise list here
New Delhi | Jagran News Desk: India's COVID-19 tally on Tuesday crossed the 11.55 lakh-mark after the country reported a surge of 37,148 new cases in the last 24 hours, said the Ministry of Health and Family Welfare while adding that 587 fatalities were reported during the same time.
According to the latest information available at the Health Ministry website, the novel coronavirus, caused by SARS‑CoV‑2, has affected 11,55,191 and claimed 28,084 in India so far. As per Health Ministry, there are 4,02,529 active coronavirus cases in India while the recovery rate is 62.72 per cent as 7,24,578 people have been cured and discharged from hospitals.
The worst-hit state in India is Maharashtra which has reported over 3.18 lakh COVID-19 cases and 12,000 deaths. Meanwhile, Tamil Nadu and Delhi have reported over 1.75 lakh and 1.23 lakh coronavirus cases respectively. Karnataka, on the other hand, has emerged as a new coronavirus hotspot in India and has reported more than 67,000 COVID-19 cases and over 1,400 deaths.
Here's the state-wise report on coronavirus pandemic in India:
|Name of State/UT||Active Cases||Cured/Discharged/Migrated||Deaths||Total Confirmed cases|
|Andaman and Nicobar Islands||55||152||0||207|
|Dadra and Nagar Haveli and Daman and Diu||234||448||2||684|
|Jammu and Kashmir||6122||8274||254||14650|
Coronavirus was first reported in China's Wuhan and since then has been spreading across the world, affecting millions. So far, scientists and researchers have failed to find a vaccine for the novel infection. However, the Oxford on Monday said that it has developed a coronavirus vaccine which is "safe, well-tolerated and immunogenic".
According to researchers at Oxford, the vaccine, ChAdOx1 nCoV-19, was tested on 1077 people in phase I and II of the human trials and none of the volunteers faced any serious effects due to it.
"The phase 1/2 Oxford COVID-19 vaccine trial is now published. The vaccine is safe, well-tolerated, and immunogenic. Congratulations to Pedro Folegatti and colleagues. These results are extremely encouraging," said Richard Horton, Editor in Chief of UK based medical Journal 'The Lancet' that published the results.
Posted By: Aalok Sensharma